Form 4: CODX Director Serbin Receives RSU Grant

Co-Diagnostics, Inc. Director Richard S. Serbin was granted 125,000 Restricted Stock Units, vesting in six installments starting November 2025.

Summary

• Director Richard S. Serbin of Co-Diagnostics, Inc. (CODX) was granted 125,000 Restricted Stock Units (RSUs) on August 13, 2025, under the Issuer's 2015 Long Term Incentive Plan, as amended.
• While each RSU generally represents the contingent right to receive one share of the Issuer's common stock, the 125,000 RSUs granted in this transaction are reported to underlie 103,333 shares of common stock.
• The RSUs will vest in six installments, commencing on November 23, 2025, and continuing every six months thereafter.
• Following this transaction, Richard S. Serbin beneficially owns a total of 228,333 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive step for corporate governance, aligning the director's long-term interests with those of shareholders. It is a routine compensation event and does not reflect on the company's operational performance, hence a moderately positive sentiment.

Positives

• The grant of Restricted Stock Units aligns the director's long-term interests with those of the shareholders, promoting shareholder value creation.

Future Outlook

The vesting schedule for the granted Restricted Stock Units indicates future equity compensation for the director, aligning their long-term commitment with the company's performance.

Industry Context

The granting of Restricted Stock Units to directors is a common and standard practice in publicly traded companies across various industries. This type of equity compensation is widely used to incentivize long-term performance and align the interests of company leadership with those of shareholders.

Comparison to Industry Standards

• Granting RSUs to directors is a common practice in publicly traded companies as a form of long-term incentive compensation. The specific number of units granted typically varies based on factors such as company size, director responsibilities, and the company's overall compensation philosophy.
• No specific comparable companies, projects, or results are detailed within this Form 4 filing to allow for a direct quantitative comparison of the grant size.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to a director constitutes a related party transaction, which is a standard form of compensation for company insiders.

Stakeholder Impact

• Shareholders: The equity grant to a director further aligns their financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic focus.

Next Steps

• The granted RSUs will begin vesting in six installments starting November 23, 2025, and continuing every six months thereafter.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to an existing director, which is a standard compensation practice. It does not contain information regarding the company's financial performance, strategic developments, or market position that would necessitate a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present new information to alter an existing investment thesis.

Keywords

Co-Diagnostics, CODX, Richard Serbin, Director, RSU, Restricted Stock Units, Equity Grant, Insider Transaction, SEC Form 4, Compensation, Incentive Plan